FindTrial
Sign In

Stemness Inhibitory Effect of miR-138 on YAP/WWTR1-driven Ovarian Cancer: an in vitro observation study

Stemness Inhibitory Effect of miR-138 on YAP/WWTR1-driven Ovarian Cancer: an in vitro observation study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200056747
Enrollment
Unknown
Registered
2022-02-13
Start date
2022-02-01
Completion date
Unknown
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer

Interventions

None listed

Sponsors

Chongqing University Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Patients with newly diagnosed stage III-IV ovarian cancer; 2. Histologically confirmed high-grade serous ovarian cancer with ascites; 3. Through preoperative evaluation, patients need to undergo (and plan to perform) paracentesis to extract ascites or surgically remove tumor tissue; 4. The patients have signed the informed consent for clinical research.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
Initial expression levels of YAP1, WWTR, CTGF and Gli genes in ovarian cancer stem cells;Inhibitory ability of miR-138 on ovarian cancer stem cells;Expression levels of YAP1, WWTR, CTGF and Gli genes in ovarian cancer stem cells after miR-138 treated;—

Countries

China

Contacts

Public ContactQi Zhou

Chongqing University Cancer Hospital

cqzl-zq@163.com+86 18717859346

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026